Paper28705809
The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer.
Hormaechea-Agulla D and 15 others. FASEB J, 2017. Cited by 42 papers, by iCite.
Cite this record
ConductScience Library. The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer. Papers, record 28705809. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28705809
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer.
- PubMed
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Alternative Splicing | Major topic |
| Gene Expression Regulation, Neoplastic | Major topic |
| MAP Kinase Signaling System | Major topic |
| Oncogene Proteins | Major topic |
| Prostatic Neoplasms | Major topic |
| Receptors, Somatostatin | Major topic |
| Wnt Signaling Pathway | Major topic |
| Aged | |
| Animals | |
| Cell Line, Tumor | |
| Heterografts | |
| Humans | |
| Male | |
| Mice | |
| Mice, Inbred BALB C | |
| Mice, Nude | |
| Middle Aged | |
| Neoplasm Metastasis | |
| Neoplasm Transplantation |
Source PubMed
Cited by31
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 42 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42941869 | G Protein-Coupled Receptors in Prostate Cancer: Pathophysiological Implications and Potential for Innovative Therapeutics. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42941869 | PubMed |
| 42135849 | Periprostatic adipose tissue-derived adipokine profile in prostate cancer patients reveals two distinct molecular phenotypes linked to obesity-related comorbidities: multifaceted role of lipocalin-2. | Cell Commun Signal | 2026 | https://conductscience.org/library/papers/42135849 | PubMed |
| 41012572 | Daunomycin Nanocarriers with High Therapeutic Payload for the Treatment of Childhood Leukemia. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/41012572 | PubMed |
| 39758250 | Clinical value of circulating splicing factors in prostate cancer: SRRM1 as a novel predictive biomarker and therapeutic target. | Mol Ther Oncol | 2024 | https://conductscience.org/library/papers/39758250 | PubMed |
| 39356765 | SRSF6 modulates histone-chaperone HIRA splicing to orchestrate AR and E2F activity in prostate cancer. | Sci Adv | 2024 | https://conductscience.org/library/papers/39356765 | PubMed |
| 39232176 | The Exon Junction Complex component EIF4A3 plays a splicing-linked oncogenic role in pancreatic ductal adenocarcinoma. | Cancer Gene Ther | 2024 | https://conductscience.org/library/papers/39232176 | PubMed |
| 38203605 | Somatostatin and Somatostatin Receptors in Tumour Biology. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/38203605 | PubMed |
| 38187140 | Altered CELF4 splicing factor enhances pancreatic neuroendocrine tumors aggressiveness influencing mTOR and everolimus response. | Mol Ther Nucleic Acids | 2024 | https://conductscience.org/library/papers/38187140 | PubMed |
| 36555216 | Gold Nanosystems Covered with Doxorubicin/DNA Complexes: A Therapeutic Target for Prostate and Liver Cancer. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36555216 | PubMed |
| 36418657 | The uprise of RNA biology in neuroendocrine neoplasms: altered splicing and RNA species unveil translational opportunities. | Rev Endocr Metab Disord | 2023 | https://conductscience.org/library/papers/36418657 | PubMed |
| 36361790 | Somatostatin, Cortistatin and Their Receptors Exert Antitumor Actions in Androgen-Independent Prostate Cancer Cells: Critical Role of Endogenous Cortistatin. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36361790 | PubMed |
| 35282415 | Dysregulation of the miRNome unveils a crosstalk between obesity and prostate cancer: miR-107 asa personalized diagnostic and therapeutic tool. | Mol Ther Nucleic Acids | 2022 | https://conductscience.org/library/papers/35282415 | PubMed |
| 35163067 | Somatostatin Receptor Splicing Variant sst5TMD4 Overexpression in Glioblastoma Is Associated with Poor Survival, Increased Aggressiveness Features, and Somatostatin Analogs Resistance. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35163067 | PubMed |
| 35086552 | SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances. | J Exp Clin Cancer Res | 2022 | https://conductscience.org/library/papers/35086552 | PubMed |
| 35008278 | Sarcopenia and Ghrelin System in the Clinical Outcome and Prognosis of Gastroenteropancreatic Neuroendocrine Neoplasms. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/35008278 | PubMed |
| 34653618 | Prostate cancer: Alternatively spliced mRNA transcripts in tumor progression and their uses as therapeutic targets. | Int J Biochem Cell Biol | 2021 | https://conductscience.org/library/papers/34653618 | PubMed |
| 34638313 | Molecular and Clinical Implications of Somatostatin Receptor Profile and Somatostatin Analogues Treatment in Oral Cavity Squamous Cell Carcinoma. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34638313 | PubMed |
| 34572980 | Comparative Cytotoxic Activity of Hydroxytyrosol and Its Semisynthetic Lipophilic Derivatives in Prostate Cancer Cells. | Antioxidants (Basel) | 2021 | https://conductscience.org/library/papers/34572980 | PubMed |
| 33948343 | Prostate cancer racial, socioeconomic, geographic disparities: targeting the genomic landscape and splicing events in search for diagnostic, prognostic and therapeutic targets. | Am J Cancer Res | 2021 | https://conductscience.org/library/papers/33948343 | PubMed |
| 33141183 | Splicing machinery dysregulation drives glioblastoma development/aggressiveness: oncogenic role of SRSF3. | Brain | 2020 | https://conductscience.org/library/papers/33141183 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| EPHB2 | 2048 | PubTator's text mining | https://conductscience.org/library/genes/2048 | NCBI Gene |
| MAPK8 | 5599 | PubTator's text mining | https://conductscience.org/library/genes/5599 | NCBI Gene |
| MYC | 4609 | PubTator's text mining | https://conductscience.org/library/genes/4609 | NCBI Gene |
| RB1 | 5925 | PubTator's text mining | https://conductscience.org/library/genes/5925 | NCBI Gene |
| SST | 6750 | PubTator's text mining | https://conductscience.org/library/genes/6750 | NCBI Gene |
| SSTR5 | 6755 | PubTator's text mining | https://conductscience.org/library/genes/6755 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28705809
GET https://conductscience.org/api/papers/v1/28705809/cited_by?page=2